Horizon Therapeutics Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Tim Walbert

Chief Executive Officer (CEO)

US$20.1m

Compensación total

Porcentaje del salario del CEO	6.4%
Permanencia del CEO	15.3yrs
Participación del CEO	n/a
Permanencia media de la dirección	2.3yrs
Promedio de permanencia en la Junta Directiva	9.5yrs

Actualizaciones recientes de la dirección

Recent updates

These 4 Measures Indicate That Horizon Therapeutics (NASDAQ:HZNP) Is Using Debt Safely

Nov 25

Analyst Forecasts Just Became More Bearish On Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

Aug 04

Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Aug 02

Horizon Therapeutics: Buy The Dip For Slightly Risky, Catalyst Driven Growth

Jul 31

Horizon gets FDA approval for Krystexxa's use with methotrexate for uncontrolled gout

Jul 08

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Tim Walbert en comparación con los beneficios de Horizon Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2023	n/a	n/a	US$438m
Mar 31 2023	n/a	n/a	US$372m
Dec 31 2022	US$20m	US$1m	US$521m
Sep 30 2022	n/a	n/a	US$574m
Jun 30 2022	n/a	n/a	US$765m
Mar 31 2022	n/a	n/a	US$862m
Dec 31 2021	US$21m	US$1m	US$534m
Sep 30 2021	n/a	n/a	US$552m
Jun 30 2021	n/a	n/a	US$518m
Mar 31 2021	n/a	n/a	US$280m
Dec 31 2020	US$22m	US$1m	US$390m
Sep 30 2020	n/a	n/a	US$792m
Jun 30 2020	n/a	n/a	US$517m
Mar 31 2020	n/a	n/a	US$592m
Dec 31 2019	US$14m	US$1m	US$573m
Sep 30 2019	n/a	n/a	US$82m
Jun 30 2019	n/a	n/a	US$97m
Mar 31 2019	n/a	n/a	US$77m
Dec 31 2018	US$17m	US$1m	-US$38m
Sep 30 2018	n/a	n/a	-US$178m
Jun 30 2018	n/a	n/a	-US$275m
Mar 31 2018	n/a	n/a	-US$460m
Dec 31 2017	US$2m	US$1m	-US$350m
Sep 30 2017	n/a	n/a	-US$495m
Jun 30 2017	n/a	n/a	-US$437m
Mar 31 2017	n/a	n/a	-US$212m
Dec 31 2016	US$2m	US$950k	-US$166m

Compensación vs. Mercado: La compensación total de Tim($USD20.10M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD13.51M).

Compensación vs. Ingresos: La compensación de Tim ha sido consistente con los resultados de la empresa en el último año.

CEO

Tim Walbert (56 yo)

15.3yrs

Permanencia

US$20,103,869

Compensación

Mr. Timothy P. Walbert, also known as Tim, serves as an Independent Director at Mirum Pharmaceuticals, Inc. from April 05, 2023. He is an Independent Director of Century Therapeutics, Inc. since September...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Timothy Walbert	Chairman	15.3yrs	US$20.10m	sin datos
Aaron Cox	Executive VP of Finance & CFO	1.4yrs	US$7.17m	0% $ 0
Sean Clayton	Executive VP & General Counsel	1.7yrs	US$10.87m	0% $ 0
Andy Pasternak	Executive VP & Chief Strategy Officer	3.9yrs	US$6.75m	0% $ 0
Elizabeth Thompson	Executive Vice President of Research & Development	2.6yrs	US$8.48m	0% $ 0
Patrick McIlvenny	Senior VP & Chief Accounting Officer	less than a year	sin datos	0% $ 0
Tina Ventura	Senior VP & Chief Investor Relations Officer	no data	sin datos	sin datos
Geoffrey Curtis	Executive VP of Corporate Affairs & Chief Communications Officer	7.8yrs	sin datos	sin datos
Keli Walbert	Executive VP & Chief Marketing Officer	less than a year	sin datos	sin datos
Jane Gonnerman	Senior VP of Corporate Development & Chief of Staff	2yrs	sin datos	sin datos
Irina Konstantinovsky	Executive VP	6.1yrs	US$2.31m	sin datos
Jeffrey Sherman	Executive VP & Chief Medical Officer	no data	US$5.86m	0% $ 0

2.3yrs

Permanencia media

48yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de HZNP se considera experimentado (2.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Timothy Walbert	Chairman	15.3yrs	US$20.10m	sin datos
Michael Grey	Lead Independent Director	12.1yrs	US$551.24k	0% $ 0
William Daniel	Independent Director	9.1yrs	US$522.49k	0% $ 0
Jeff Himawan	Independent Director	16.3yrs	US$504.36k	0% $ 0
Gino Santini	Independent Director	11.6yrs	US$494.99k	0% $ 0
H. Watkins	Independent Director	9.5yrs	US$506.24k	0% $ 0
James Shannon	Independent Director	6.2yrs	US$510.61k	0% $ 0
Susan Mahony	Independent Director	4.2yrs	US$514.36k	0% $ 0
Pascale Witz	Independent Director	6.2yrs	US$496.24k	0% $ 0

9.5yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: La junta directiva de HZNP se considera experimentada (9.5 años de antigüedad promedio).

Horizon Therapeutics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

Executive VP & Chief Strategy Officer exercised options and sold US$348k worth of stock

Executive VP & Chief Strategy Officer notifies of intention to sell stock

Executive VP & Chief Strategy Officer notifies of intention to sell stock

Recent updates

Health Canada Approves Horizon Therapeutics plc 's UPLIZNA® (inebilizumab for injection) for the Treatment of Neuromyelitis Optica Spectrum Disorders

Horizon Therapeutics Public Limited Company Files Form 15

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from S&P Global BMI Index

Horizon Therapeutics Public Limited Company Announces New Analysis of Adhering to Uninterrupted Full Course of Treatment with Tepezza to Support Thyroid Eye Disease Patient Outcomes

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart for Severe Alopecia Areata

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Horizon Therapeutics Public Limited Company to Report Q2, 2023 Results on Aug 08, 2023

Horizon Therapeutics plc Announces New Analysis of MRI Findings Shows UPLIZNA®? (inebilizumab-cdon) Reduced the Formation of Subclinical Spinal Cord Lesions in People with Neuromyelitis Optica Spectrum Disorder

Horizon Therapeutics plc Announces Tepezza® (Teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease

Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (Optic-J) in Japan

Horizon Therapeutics plc Announces Additional Data from Phase 4 TEPEZZA® (teprotumumab-trbw) Clinical Trial Presented at the Endocrine Society Annual Meeting Reinforces Efficacy in People with Thyroid Eye Disease (TED) Regardless of Disease Activity or Duration

Horizon Therapeutics plc Announces the Publication of New Analysis from the N-MOmentum Clinical Trial of UPLIZNA Demonstrating the Utility of A Robust Assay Process

Horizon Therapeutics plc Announces Data from the Teprotumumab Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease

Horizon Therapeutics plc Announces the Publication of New Data from the Phase 3 N-MOmentum Pivotal Trial of UPLIZNA

Horizon Therapeutics plc Announces Presentations At the 2023 Eular European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjögren’S Syndrome

Horizon Therapeutics Public Limited Company to Report Q4, 2022 Results on Mar 01, 2023

Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus

Amgen Inc. (NasdaqGS:AMGN) entered into a transaction agreement to acquire Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP) for $27.1 billion.

Amgen Reportedly in Advanced Talks to Buy Horizon Therapeutics

Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout

Investor sentiment improved over the past week

These 4 Measures Indicate That Horizon Therapeutics (NASDAQ:HZNP) Is Using Debt Safely

Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (Optic-J) in Japan Evaluating Tepezza® for the Treatment of Active Thyroid Eye Disease

Insufficient new directors

Horizon Therapeutics plc Announces That Month 12 Data from the Mirror Randomized Controlled Trial of Krystexxa® (Pegloticase) Injection

Horizon Therapeutics plc Announces That Month 12 Data from the Mirror Randomized Controlled Trial of Krystexxa® (Pegloticase) Injection

Investor sentiment improved over the past week

Horizon Therapeutics Public Limited Company Announces Data Support the Use of KRYSTEXXA (Pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People with Mild-To-Moderate Chronic Kidney Disease

Executive VP & Chief Strategy Officer exercised options and sold US$348k worth of stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Horizon Therapeutics Public Limited Company Revises Earnings Guidance for the Full Year 2022

Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis

Horizon Therapeutics plc Announces New Data from Two Analyses of the Uplizna Phase 3 Pivotal Trial Presented At the 38(Th) Congress of the European Committee for Treatment and Research in Multiple Sclerosis (Ectrims 2022), Oct. 26-28 in Amsterdam

Horizon Therapeutics Public Limited Company to Report Q3, 2022 Results on Nov 02, 2022

Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (Teprotumumab-Trbw) in Adults with Chronic/Low Clinical Activity Score (Cas) Thyroid Eye Disease (Ted)

Horizon pays HemoShear milestone payment under pact to develop gout therapies

Horizon Therapeutics plc Announces Data from the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection with Methotrexate Published in Arthritis & Rheumatology

Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint

Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP) announces an Equity Buyback for $500 million worth of its shares.

Horizon Therapeutics announces $500M buyback program

Horizon Therapeutics to expand footprint in Ireland

Is Horizon Therapeutics (NASDAQ:HZNP) A Risky Investment?

Horizon Therapeutics: This Core Biotech Company Is On Sale

Consensus revenue estimates fall by 10%

Executive VP & Chief Strategy Officer notifies of intention to sell stock

Price target decreased to US$114

Analyst Forecasts Just Became More Bearish On Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

Horizon Therapeutics Public Limited Company Reports Impairment of Goodwill for the Second Quarter Ended June 30, 2022

Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Horizon Therapeutics: Buy The Dip For Slightly Risky, Catalyst Driven Growth

FDA Approves KRYSTEXXA® (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy

Horizon gets FDA approval for Krystexxa's use with methotrexate for uncontrolled gout

Horizon Therapeutics Public Limited Company to Report Q2, 2022 Results on Aug 03, 2022

Horizon Therapeutics Public Limited Company Announces New Analysis Finds UPLIZNA (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Executive VP & Chief Strategy Officer notifies of intention to sell stock

Horizon Therapeutics plc Submits Regulatory Filing for Uplizna® (Inebilizumab) in Brazil

Horizon Therapeutics Public Limited Company Announces Results of A New Analysis Examining Rates of Hyperglycemia Among Patients Treated with TEPEZZA for TED Compare to Placebo in the Phase 2 and OPTIC Phase 3 Clinical Trials

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media